Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clomipramine and obsessive-compulsive disorder

L Scahill, K A Lynch

    Journal of Child and Adolescent Psychiatric Nursing : Official Publication of the Association of Child and Adolescent Psychiatric Nurses, Inc
    |April 1, 1995
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Development of a novel parent-report measure of food allergy impact.

    Acta paediatrica (Oslo, Norway : 1992)·2024
    Same author

    Qualitative Exploration Toward the Development of a Parent-Rated Scale for Insomnia in Children with Autism Spectrum Disorder.

    Journal of autism and developmental disorders·2023
    Same author

    Feasibility of Actigraphy for Evaluating Sleep and Daytime Physical Activity in Children with Autism Spectrum Disorder.

    Journal of autism and developmental disorders·2022
    Same author

    Auroral ionospheric plasma flow extraction using subsonic retarding potential analyzers.

    The Review of scientific instruments·2020
    Same author

    A small spacecraft for multipoint measurement of ionospheric plasma.

    The Review of scientific instruments·2017
    Same author

    Successful pharmacotherapy for the treatment of severe feeding aversion with mechanistic insights from cross-species neuronal remodeling.

    Translational psychiatry·2017

    Clomipramine (CMI) effectively treats Obsessive-Compulsive Disorder (OCD) by blocking serotonin reuptake. However, potential side effects and varied patient responses necessitate careful clinical monitoring and suggest other neurochemical factors may be involved in OCD.

    Area of Science:

    • Pharmacology
    • Neuroscience
    • Psychiatry

    Background:

    • Clomipramine (CMI) is a tricyclic antidepressant, recognized as the first effective treatment for Obsessive-Compulsive Disorder (OCD).
    • CMI's efficacy is primarily attributed to its potent serotonin reuptake inhibition, which targets core OCD symptoms.
    • As a tricyclic agent, CMI presents a spectrum of potential side effects affecting gastrointestinal, autonomic, hepatic, and cardiac systems, requiring careful consideration in pediatric and adolescent populations.

    Purpose of the Study:

    • To review the role of Clomipramine in Obsessive-Compulsive Disorder treatment.
    • To highlight the importance of monitoring therapeutic response and potential adverse effects.
    • To explore the variability in patient response to CMI and its implications for understanding OCD neurochemistry.

    Related Experiment Videos

    Main Methods:

    • Review of Clomipramine's mechanism of action in OCD.
    • Discussion of clinical management strategies, including target symptom identification and monitoring.
    • Mention of assessment tools like the Children's Yale-Brown Obsessive Compulsive Scales and plasma drug levels.

    Main Results:

    • Clomipramine demonstrates efficacy in reducing primary symptoms of OCD through serotonin reuptake blockade.
    • Clinical response evaluation involves tracking target symptom changes over time.
    • A significant portion of OCD patients exhibit a positive response to CMI, while others do not respond, indicating potential heterogeneity in the disorder.

    Conclusions:

    • Clomipramine remains a key pharmacological agent for OCD, with serotonin reuptake inhibition as its principal mechanism.
    • Effective management requires vigilant monitoring for side effects and assessment of treatment response using validated instruments.
    • The observed variability in CMI response suggests that additional neurochemical pathways likely contribute to the pathophysiology of OCD, warranting further investigation.